Back to results
US 2021/0330677 A1Published application
Pkc inhibitors for the treatment of septic cholestasis with ctm targeting
AssigneeSmartdyelivery GmbH
InventorsChristoph ENZENSPERGER, Marc LEHMANN
Life of this patent
Estimating the term…
Abstract
The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.
Claims21
-13. (canceled)
A nanostructured delivery system, comprising:
- an inhibitor of a protein kinase C (PKC) signaling pathway;
- at least one carbohydrate targeting moiety;
- and
- a carrier,
- wherein the nanostructured delivery system is adapted for treating septic cholestasis by lowering or inhibiting PKC in liver cells.
2 more elements
Dependencies are inferred from the claim text.